ASX-listed digital health company ResApp is working with telehealth software developer Coviu to integrate ResApp’s acute respiratory diagnostic app into Coviu’s platform to help clinicians diagnose respiratory disease in a telehealth setting.

ResAppDx-EU is a TGA-approved smartphone app that uses machine learning algorithms that analyse a patient’s cough sounds to diagnose disease.